Lucintel's latest market report analyzed that gastrointestinal drug provides attractive opportunities in the cure of gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome disorders/applications. The gastrointestinal drug market is expected to reach $XX billion by 2027 with a CAGR of 4% to 6%. In this market, acid neutralizers is the largest segment by drug class.
Download Brochure of this report by clicking on https://www.lucintel.com/gastrointestinal-drug-market.aspx
Based on drug class, the gastrointestinal drug market is segmented into acid
neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants,
anti-inflammatory drugs, biologics, others (antispasmodic etc.). The acid
neutralizers segment accounted for the largest share of the market in 2022 and
is expected to register the highest CAGR during the forecast period, due to the
increasing consumption of antacid by growing geriatric population that are
suffering from Gastroesophageal Reflux Disease (GERD), higher incidences of
acidity due to unhealthy lifestyle, and side-effects of non-steroidal drugs and
anti-inflammatory drugs.
Browse in-depth TOC on
“Gastrointestinal Drug Market”
70 – Tables
90 – Figures
180 – Pages
The Gastrointestinal Drug
Market is marked by the presence of several big and small players. Some of the
prominent players offering gastrointestinal drug include Takeda
Pharmaceuticals, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson,
AbbVie Inc. (Allergan Plc), Bausch Health Companies Inc. (Valeant
Pharmaceuticals Inc.), Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc.
Request Sample Report:
https://www.lucintel.com/gastrointestinal-drug-market.aspx
This unique research report will enable you
to make confident business decisions in this globally competitive marketplace. For
a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on
this link helpdesk@lucintel.com.
About Lucintel
Lucintel,
the premier global management consulting and market research firm, creates
winning strategies for growth. It offers market assessments, competitive
analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
Brandon Fitzgerald
Lucintel
Dallas,
Texas, USA
Email: brandon.fitzgerald@lucintel.com
Tel. 972.636.5056
Cell: 303.775.0751
Related reports
Mhealth
Solution Market:
For more details click here https://www.lucintel.com/mhealth-solution-market.aspx
Minimally
Invasive Surgery Market:
For more details click here https://www.lucintel.com/minimally-invasive-surgery-market.aspx
Medical Aesthetic Market:
For more details click here https://www.lucintel.com/medical-aesthetic-market.aspx
Neurostimulation Market:
For more details click here https://www.lucintel.com/neurostimulation-market.aspx
Nuclear Medicine/Radiopharmaceutical Market:
For more details click here https://www.lucintel.com/nuclear-medicine-radiopharmaceutical-market.aspx
Liquid Biopsy Market:
For more details click here https://www.lucintel.com/liquid-biopsy-market.aspx
Digital
Fitness Market:
For more details click here https://www.lucintel.com/digital-fitness-market.aspx
Digital X-Ray Market:
For more details click here https://www.lucintel.com/digital-xray-market.aspx
Medical
Robot Market:
For more details click here https://www.lucintel.com/medical-robot-market.aspx
Healthcare IT Market:
No comments:
Post a Comment